Fractional Concentration of Exhaled NO(FeNO) to Direct The Treatment of Sub-acute Cough
Status:
Unknown status
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
Cough is a common symptom that leads patients worldwide to seek medical attention. Subacute
cough refers to a cough of 3-8-week duration, and is typically refractory to standard
anti-tussive therapy, and a tendency to spontaneous healing was common. Few clinical trials
have evaluated therapeutic options for subacute cough. Airway inflammation is an important
feature of most of subacute cough, Cysteinyl leukotrienes and FeNO correlates with airway
inflammation. Subacute cough often represents a prolonged post-viral response. Cysteinyl
leukotrienes increase in virus infection. Airway inflammation induce epithelial cells produce
iNOS(inducible nitric oxide synthase,iNOS), and FeNO increase in theory. Montelukast is a
cysteinyl leukotriene type 1 receptor antagonist that is reported to improve cough16 and
reduces FENO and prevents increases in FENO during reduction of inhaled corticosteroid dose,
But A meta-analysis of the effectiveness of LTRA( leukotriene receptor antagonist,LTRA)in
treating children with prolonged non-specific cough concluded that, with the lack of
evidence, the routine use of LTRA in treating children with non-specific cough cannot be
recommended. A randomised, placebo-controlled trial showed montelukast is not an effective
treatment for postinfectious cough. Non-specialists or general practitioners of Japan
prescribe LTRA very often, which increase. The aim is to research whether FeNO can be used as
a biomarker to direct montelukast treatment and optimize treatment regimen of sub-acute
cough.